Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
661-680 of 2,120 trials

Genitourinary Syndrome of Menopause: Cellular Matrix Treatment

We are studying a new treatment combining platelet-rich plasma and hyaluronic acid for women with genitourinary syndrome of menopause. This trial compares its effects to a standard estrogen gel to see which works better for symptom relief.

Genitourinary Syndrome of Menopause3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesGynecology and Obstetrics

Upper Limb Spasticity: New Botulinum Toxin Treatment

We are investigating a new injection for adults with upper limb spasticity to see if it is safe and effective compared to existing treatments. This study will help us understand how well it works over time.

Upper Limb Spasticity1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Cervical Cancer: Fertility-Sparing Treatment Study

We are studying a new approach for women with early-stage cervical cancer to see if chemotherapy followed by surgery can help preserve fertility. This trial aims to evaluate the safety and effectiveness of this treatment method.

Cervical Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Immunoglobulin A Nephropathy: Sibeprenlimab Study

We are testing the safety and effectiveness of Sibeprenlimab for people with Immunoglobulin A Nephropathy. This study aims to see how well it works in managing the condition and its impact on kidney health.

IgA Nephropathy>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNephrology

Severe Hyponatremia: DDAVP Treatment Study

We are investigating whether DDAVP can help prevent sodium overcorrection in patients with severe hyponatremia. This study aims to improve safety and outcomes for those experiencing dangerously low sodium levels.

Low Sodium Levels (Hyponatremia)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Ulcerative Colitis: Adalimumab Treatment Comparison

We are comparing a new treatment approach with telemonitoring and education to standard care for patients starting adalimumab. The aim is to see if this helps manage ulcerative colitis more effectively.

Ulcerative Colitis>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Hemophilia B: REGV131-LNP1265 Gene Therapy

We are studying a new gene therapy to see if it is safe and helps adults with Hemophilia B produce a vital clotting factor. The trial will also assess how it affects bleeding events.

Hemophilia B>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Familial Hypercholesterolemia: Inclisiran Safety Study

We are studying the long-term safety and tolerability of inclisiran in individuals with familial hypercholesterolemia who have completed earlier studies. This research aims to understand how well the treatment works over time.

Familial Hypercholesterolemia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Pneumonia Prevention: 20-Valent Pneumococcal Vaccine

We are studying whether a new 20-valent pneumococcal vaccine helps prevent pneumonia in adults aged 65 and older. This trial will assess its effectiveness against specific types of pneumonia caused by certain bacteria.

Community Acquired Pneumonia>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesPulmonology

HER2-Positive Breast Cancer: Trastuzumab and Pertuzumab Study

We are exploring a new treatment approach for patients with HER2-positive unresectable locally advanced or metastatic breast cancer. This study aims to see how well this treatment works and its safety compared to existing options.

HER2-positive Metastatic Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Dupuytren's Contracture: Bacterial Collagenase Treatment

We are studying a new bacterial collagenase injection for patients with Dupuytren's contracture to see if it improves hand function and reduces contracture compared to a placebo.

Dupuytren's Contracture6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsInvestigational MedicinesOrthopedics and TraumatologyRheumatology

HER2-Low Metastatic Breast Cancer: DB-1303 vs Chemotherapy

We are studying a new treatment, DB-1303, for patients with HER2-low, hormone receptor-positive metastatic breast cancer. The goal is to see if it works better than standard chemotherapy after previous treatments have failed.

Hormone Receptor Positive Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ongoing Treatment with Durvalumab for Cancer Patients

We are providing continued treatment for patients who have benefited from Durvalumab in a previous study. The focus is on monitoring safety and tolerability during this ongoing care.

Advanced Non-Small Cell Lung CancerPost-Chemotherapy Urothelial CarcinomaExtensive Stage Small-Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

COVID-19 Vaccine: Preventing Type 1 Diabetes in At-Risk Children

We are studying if vaccinating children with a higher genetic risk for type 1 diabetes against COVID-19 can lower their chances of developing diabetes and related autoimmune conditions. This research aims to see if the vaccine can help protect their health.

Risk for Type 1 Diabetes>2 yearsMonitoring phase (IV)11-15 visitsStandard MedicinesCost ReimbursementEndocrinologyInfectious Diseases

Generalized Myasthenia Gravis: Efgartigimod Safety Study

We are studying the safety of efgartigimod given through IV and injection in children with generalized myasthenia gravis. This trial aims to ensure the treatment is safe and well-tolerated.

Myasthenia GravisEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Long-Term Safety Study of NTLA-2001

We are evaluating the long-term safety and effects of NTLA-2001 in participants who have already received this treatment. This study aims to understand how it impacts their health over time.

Hereditary Amyloidosis>2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNeurology

Multiple Myeloma: Iberdomide with Isatuximab

We are studying whether adding isatuximab to iberdomide helps patients with newly diagnosed multiple myeloma achieve better treatment outcomes after stem cell transplantation.

Multiple Myeloma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Low Back Pain: PRGF-Endoret® Treatment Study

We are investigating whether PRGF-Endoret® can effectively reduce pain and enhance quality of life in patients with chronic low back pain due to disc degeneration, compared to standard treatments.

Low Back PainMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

COVID-19 Treatment: RECOVERY Trial

We are studying various treatments for COVID-19 to see if they can reduce death rates and help patients leave the hospital sooner. We also want to find out if these treatments can prevent severe breathing issues.

Pneumonia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Chronic Kidney Disease: CKD-bioMatch Study

We are exploring whether a new treatment based on biomarkers can improve kidney function in patients with chronic kidney disease compared to standard care. This study aims to find better ways to manage CKD and its effects.

Chronic Kidney Disease>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementNephrology